Outcomes after first-line immunochemotherapy for primary mediastinal B-cell lymphoma: a LYSA study.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
12 10 2021
12 10 2021
Historique:
received:
18
03
2021
accepted:
04
05
2021
pubmed:
31
8
2021
medline:
3
11
2021
entrez:
30
8
2021
Statut:
ppublish
Résumé
Primary mediastinal B-cell lymphoma (PMBL) is a rare type of aggressive lymphoma typically affecting young female patients. The first-line standard of care remains debated. We performed a large multicenter retrospective study in 25 centers in France and Belgium to describe PMBL patient outcomes after first-line treatment in real-life settings. A total of 313 patients were enrolled and received rituximab (R) plus ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) (n = 180) or CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) delivered every 14 days (R-CHOP14, n = 76) or 21 days (R-CHOP21, n = 57) and consolidation strategies in modalities that varied according to time and institution, mainly guided by positron emission tomography. Consolidation autologous stem cell transplantation was performed for 46 (25.6%), 24 (31.6%), and 1 (1.8%) patient in the R-ACVBP, R-CHOP14, and R-CHOP21 groups, respectively (P < .001); only 17 (5.4%) patients received mediastinal radiotherapy. The end-of-treatment complete metabolic response rates were 86.3%, 86.8%, and 76.6% (P = .23) in the R-ACVBP, R-CHOP14, and R-CHOP21 groups. The median follow-up was 44 months, and the R-ACVBP, R-CHOP14, and R-CHOP21 three-year progression-free survival probabilities were 89.4% (95% confidence interval [CI], 84.8-94.2), 89.4% (95% CI, 82.7-96.6), and 74.7% (95% CI, 64-87.1) (P = .018). A baseline total metabolic tumor volume (TMTV) ≥360 cm3 was associated with a lower progression-free survival (hazard ratio, 2.18; 95% CI, 1.05-4.53). Excess febrile neutropenia (24.4% vs 5.3% vs 5.3%; P < .001) and mucositis (22.8% vs 3.9% vs 1.8%; P < .001) were observed with R-ACVBP compared with the R-CHOP regimens. Patients with PMBL treated with dose-dense immunochemotherapy without radiotherapy have excellent outcomes. R-ACVBP acute toxicity was higher than that of R-CHOP14. Our data confirmed the prognostic importance of baseline TMTV.
Identifiants
pubmed: 34461634
pii: S2473-9529(21)00453-5
doi: 10.1182/bloodadvances.2021004778
pmc: PMC8679665
doi:
Substances chimiques
Antibodies, Monoclonal, Murine-Derived
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3862-3872Informations de copyright
© 2021 by The American Society of Hematology.
Références
Blood. 2011 Feb 10;117(6):1806-16
pubmed: 21037086
Clin Lymphoma Myeloma Leuk. 2018 Dec;18(12):781-787
pubmed: 30262330
Leuk Lymphoma. 2009 Aug;50(8):1257-60
pubmed: 19544140
PLoS One. 2019 Feb 7;14(2):e0211649
pubmed: 30730936
Blood. 2004 Aug 1;104(3):634-41
pubmed: 15016643
N Engl J Med. 2013 Apr 11;368(15):1408-16
pubmed: 23574119
Blood. 2011 Jul 7;118(1):37-43
pubmed: 21518924
J Clin Oncol. 2007 Feb 10;25(5):579-86
pubmed: 17242396
Lancet. 2011 Nov 26;378(9806):1858-67
pubmed: 22118442
Blood. 2020 Dec 10;136(24):2803-2811
pubmed: 32603413
Lancet Oncol. 2008 Feb;9(2):105-16
pubmed: 18226581
Ann Hematol. 2021 Sep;100(9):2261-2268
pubmed: 33305333
Haematologica. 2018 Aug;103(8):1337-1344
pubmed: 29748435
Clin Cardiol. 2017 Apr;40(4):255-261
pubmed: 28139844
Lancet Oncol. 2013 May;14(6):525-33
pubmed: 23578722
Leuk Lymphoma. 2011 Apr;52(4):604-12
pubmed: 21261504
Leuk Lymphoma. 2019 May;60(5):1261-1265
pubmed: 30656983
Blood. 2020 Dec 10;136(24):2725-2726
pubmed: 33301033
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):42-49
pubmed: 27839910
Leuk Lymphoma. 2015 Jan;56(1):57-64
pubmed: 24628294
J Clin Oncol. 1994 Feb;12(2):312-25
pubmed: 8113838
Blood. 2021 Apr 29;137(17):2307-2320
pubmed: 33211799
Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1239-43
pubmed: 27130796
Blood. 2003 Dec 15;102(13):4284-9
pubmed: 12920037
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S77-85
pubmed: 20171522
Blood. 2004 Feb 15;103(4):1222-8
pubmed: 14576060
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2018-2024
pubmed: 28634685
Haematologica. 2011 Aug;96(8):1136-43
pubmed: 21546499
Medicine (Baltimore). 2016 Jul;95(27):e4054
pubmed: 27399089
Hematology Am Soc Hematol Educ Program. 2008;:349-58
pubmed: 19074109
Leuk Lymphoma. 2008 Aug;49(8):1510-5
pubmed: 18766963
Hematology. 2017 Jun;22(5):258-264
pubmed: 27884092
Br J Haematol. 2018 Feb;180(4):534-544
pubmed: 29265182
Leuk Lymphoma. 2013 Aug;54(8):1684-90
pubmed: 23137070
Cancer Chemother Pharmacol. 2016 May;77(5):1053-60
pubmed: 27056383
J Clin Oncol. 2019 Dec 1;37(34):3291-3299
pubmed: 31609651
Cancer Med. 2019 Aug;8(10):4626-4632
pubmed: 31264808
J Clin Oncol. 1995 Mar;13(3):588-95
pubmed: 7884420
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1289-95
pubmed: 23245279
Blood. 2017 Sep 14;130(11):1315-1326
pubmed: 28701367
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Biol Blood Marrow Transplant. 2018 Oct;24(10):2133-2138
pubmed: 29909154
Heart. 2018 Jun;104(12):971-977
pubmed: 29217634
Blood Cancer J. 2015 Dec 04;5:e372
pubmed: 26636287
Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):113-21
pubmed: 25863759
Hematol Oncol. 2013 Mar;31(1):10-7
pubmed: 22610484
Blood. 2018 Aug 23;132(8):782-790
pubmed: 29976557
Blood. 2017 Jun 8;129(23):3059-3070
pubmed: 28416502
J Clin Oncol. 2017 Jun 20;35(18):2008-2017
pubmed: 28459613
Leuk Lymphoma. 2008 Jul;49(7):1329-36
pubmed: 18604722
Haematologica. 2014 Dec;99(12):1817-25
pubmed: 25216682
J Clin Oncol. 2009 Sep 10;27(26):4239-46
pubmed: 19667275
Bone Marrow Transplant. 2018 Aug;53(8):1001-1009
pubmed: 29463854